Hide metadata

dc.date.accessioned2024-03-13T22:30:42Z
dc.date.available2024-03-13T22:30:42Z
dc.date.created2023-03-14T09:19:50Z
dc.date.issued2023
dc.identifier.citationAbu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine Ballestad Langseth, Hilde Meese, Eckart Keller, Verena . Dynamic and static circulating cancer microRNA biomarkers – a validation study. RNA Biology. 2023, 20(1), 1-9
dc.identifier.urihttp://hdl.handle.net/10852/109558
dc.description.abstractFor cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from cancer-free controls. Each patient provided at least two serum samples, one prior to diagnosis and one following diagnosis. The median time interval between the samples was 11.6 years. Using computational models, we evaluated the circulating profiles of 21 microRNAs. The analysis yielded two sets of biomarkers, static ones that show an absolute difference between certain cancer types and controls and dynamic ones where the level over time provided higher diagnostic information content. In the first group, miR-99a-5p stands out for all three cancer types. In the second group, miR-155-5p allows to predict lung cancers and colon cancers. Classification in samples from cancer and non-cancer patients using gradient boosted trees reached an average accuracy of 79.9%. The results suggest that individual change over time or an absolute value at one time point may predict a disease with high specificity and sensitivity.
dc.languageEN
dc.publisherLandes Bioscience
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleDynamic and static circulating cancer microRNA biomarkers – a validation study
dc.title.alternativeENEngelskEnglishDynamic and static circulating cancer microRNA biomarkers – a validation study
dc.typeJournal article
dc.creator.authorAbu-Halima, Masood
dc.creator.authorKeller, Andreas
dc.creator.authorBecker, Lea Simone
dc.creator.authorFischer, Ulrike
dc.creator.authorEngel, Annika
dc.creator.authorLudwig, Nicole
dc.creator.authorKern, Fabian
dc.creator.authorRounge, Trine Ballestad
dc.creator.authorLangseth, Hilde
dc.creator.authorMeese, Eckart
dc.creator.authorKeller, Verena
cristin.unitcode185,15,23,30
cristin.unitnameSeksjon for farmakologi og farmasøytisk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2133667
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RNA Biology&rft.volume=20&rft.spage=1&rft.date=2023
dc.identifier.jtitleRNA Biology
dc.identifier.volume20
dc.identifier.issue1
dc.identifier.startpage1
dc.identifier.endpage9
dc.identifier.doihttps://doi.org/10.1080/15476286.2022.2154470
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1547-6286
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International